Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

19.07.2021 | short review | Ausgabe 3/2021 Open Access

memo - Magazine of European Medical Oncology 3/2021

Novel agents in a young patient with osteosarcoma: A short review

memo - Magazine of European Medical Oncology > Ausgabe 3/2021
Dr. Oskar Steinbrecher, ao. Univ. Prof. Dr. Thomas Brodowicz, Assoc. Prof. PD Dr. Wolfgang Lamm
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Osteosarcomas are rare malignancies, which most commonly occur in children as well as adolescents and young adults, aged between 15–25 years [ 1]. Initially localized osteosarcoma is generally treated with neoadjuvant chemotherapy followed by surgical resection and adjuvant chemotherapy [ 2, 3]. Osteosarcomas nevertheless frequently develop isolated pulmonary relapses, which are commonly treated with complete metastasectomy if possible, even in consecutively relapsed disease [ 4, 5]. However, data on systemic treatment options after pulmonary relapse are limited; therefore, treatments are mostly assigned individually in a patient-tailored setting [ 2]. In this article, we describe a patient treated with various systemic treatments after metastasectomy and briefly summarize the current literature.

Case report

We describe the case of a 19-year-old woman who consulted her general practitioner in July 2013 due to acute and increasing pelvic pain. A computed tomography (CT) scan showed a suspicious mass of the left hemipelvis with a maximum diameter of 15.5 cm (Fig.  1). Subsequently, she was referred to the Vienna General Hospital, Medical University of Vienna, a specialized sarcoma center. Open biopsy and subsequent histopathology revealed a high grade, G3, mixed osteoblastic (20%) and chondroblastic (80%) osteosarcoma. Abdominal and chest CT scan showed no metastases. Therefore, in compliance with the recent guidelines, first-line therapy according to the EURAMOS‑1 protocol was initiated [ 2]. Thus, neoadjuvant therapy for 10 weeks consisting of 120 mg/m 2 cisplatin (P) and 75 mg/m 2 doxorubicin (A) (weeks 1 and 6), followed by 12 g/m 2 high dose methotrexate (M) (weeks 4, 5, 9 and 10) were administered. Subsequently, tumor excision performing limb-sparing left-sided hemipelvectomy was performed.
Postoperative histopathology showed a complete resection (R0 resection) with a high extraosseous proportion and 20% vital tumor cells. Thus, the patient was classified as a nonresponder to neoadjuvant treatment (regression grade IV) and was subsequently assigned to adjuvant MAPIE over 28 weeks (MAP with additional ifosfamide and etoposide). Ifosfamide at the dose of 3 g/m 2 was given with doxorubicin over 3 days in cycles designated as AI, and at dose of 2800 mg/m 2 with etoposide 100 mg/m 2 over 5 days in designated IE cycles, according to the EURAMOS‑1 trial [ 6].
Due to neutropenic fever after IE administration (week 16), a 50% dose reduction was necessary starting from week 19 until the end of treatment at week 39 in October 2014. The scheduled week 40 (M) was omitted due to increased liver enzymes, attributed to delayed M elimination in weeks 35 and 39.
Follow-up imaging via CT scan of thorax and abdomen as well as magnetic resonance imaging (MRI) of the pelvis was performed at 3 month intervals. In October 2015, a 5 mm lesion in the lower lobe of the left lung was identified in a chest CT scan, approximately 1 year after therapy completion. Following international guidelines, complete pulmonary metastasectomy was performed. Histopathology showed a metastasis of the chondroblastic osteosarcoma with R0 resection. Current guidelines do not recommend adjuvant treatment after complete pulmonary metastasectomy [ 4, 7]. However, we chose to start adjuvant treatment in hopes of prolonging the time to potential recurrence of further pulmonary metastases and given the simple oral administration of pazopanib at home.
In June 2016, after 8 months of oral adjuvant pazopanib treatment, a CT scan showed 3 pulmonary nodules (left lower lobe: 19 mm, lingula: 5 mm and right upper lobe: 4 mm). Another R0 metastasectomy of all 3 pulmonary lesions was performed and experimental therapy with pembrolizumab 200 mg every 21 days was initiated. The interval between applications of pembrolizumab was prolonged to 28 days due to pembrolizumab-induced blepharoconjunctivitis, which was successfully treated with local corticosteroids. Therapy with pembrolizumab was administered from August 2016 until July 2018, when again, a single pulmonary metastasis (right upper lobe: 4 mm) was diagnosed.
A third R0 metastasectomy was performed, and an oral third-line treatment with 28-day cycles of regorafenib, another multitargeted TKI (tyrosine kinase inhibitor), at a daily dose of 40 mg, for the first 21 days of each cycle, was initiated. Apart from regorafenib-induced substitution-dependent hypothyroidism, no side effects were noted, and therapy was continued on schedule. Currently, the patient is followed up with CT scans of the thorax and abdomen every 6 months and annual MRI. Recent CT scans, 28 months after initiation of regorafenib, showed NED (no evidence of disease), regorafenib therapy is still ongoing and the patient is in excellent general condition (ECOG 0). Due to good tolerance, therapy will be continued until disease progression.

Discussion and short review

In this article, we present the case of a young patient undergoing local surgery, chemotherapy as well as therapy with novel agents for recurring osteosarcoma.
In 2013, according to the EURAMOS‑1 trial, our patient received neoadjuvant MAP and was postoperatively randomly assigned to receive MAPIE, due to the classification as a nonresponder to neoadjuvant treatment (regression grade IV). However, in 2016, published data reported increased toxicity without survival improvement of MAPIE compared to MAP alone [ 6]. Therefore, current guidelines recommend local surgery as well as neoadjuvant and adjuvant treatment with only MAP in all young patients with initially localized disease [ 2].
Recurrence rates in bone sarcomas with complete response to initial treatment have been reported to be 20–40% [ 8]. In case of relapse with isolated lung metastasis, complete surgical resection, if possible, is the treatment of choice, even in consecutive relapses and is often accompanied by chemotherapy [ 9]. A possible chemotherapeutic option in relapsed osteosarcoma is high-dose ifosfamide with an overall response rate (ORR) of approximately 20–30% [ 10]. Besides ifosfamide, the use of gemcitabine and docetaxel as well as cyclophosphamide and etoposide in relapsed or refractory osteosarcoma is feasible [ 11, 12]. If surgery is not possible, stereotactic radiotherapy, cryotherapy or radiofrequency ablation are alternative treatment options. Evidence even suggests an effect of radiofrequency ablation and stereotactic radiotherapy as first-line treatments of resectable lung metastasis [ 1214]. Only limited data exist in adjuvant therapy after pulmonary metastasectomy. Predina et al., for example, reported no differences in disease-free survival after pulmonary metastasectomy for soft tissue sarcoma with adjuvant chemotherapy versus no chemotherapy ( p = 0.88) [ 15]. According to guidelines, watch and wait strategy is the treatment of choice in relapsed osteosarcoma patients with lung metastasis after R0 resection [ 7]. In this particularly young patient, however, a maximum therapy approach was chosen in hopes of prolonging disease-free survival.
Because our patient had already received first-line ifosfamide in the MAPIE arm, and did not wish any further intravenous chemotherapy treatment, other adjuvant therapeutic options had to be offered to her.
Trials investigating the efficacy of different novel treatment options, such as TKIs in osteosarcomas are scarce [ 1618]. Studies on sorafenib, for example, showed an ORR between 5 and 9% in two trials in advanced bone sarcoma patients [ 19, 20]. Data on the use of pazopanib, a second generation TKI, in osteosarcoma are mostly limited to small case series, demonstrating median overall survivals between 3 and 11 months in the metastatic setting [ 17, 18, 21]. Since R0 metastasectomy was achieved and our patient was already heavily pretreated with chemotherapy, application of off-label pazopanib was established. Therapy was well tolerated, but tumor recurrence in the lung occurred 6 months after initiation of therapy, which is nevertheless in the range of tumor control reported previously [ 17, 18, 21].
In addition to TKIs, checkpoint inhibitors (CPI) have gained much attention in the last decade due to their widespread use in various oncologic diseases [ 22, 23]. Therefore, after failure of pazopanib and second pulmonary R0 resection, experimental off-label treatment with pembrolizumab was initiated. A total of 28 cycles of pembrolizumab were administered until a third pulmonary relapse was diagnosed. During treatment with pembrolizumab, the patient showed NED over a period of 23 months with manageable side effects. However, phase II studies on the use of pembrolizumab in advanced unresectable or metastatic osteosarcoma published later showed mostly negative results with low or no antitumor effect [ 2426]. In view of this, it is difficult to assess whether the course in our patient was a natural progression or if pembrolizumab had some sort of delaying effect. However, the fact that prior progression had occurred 17 months earlier makes it tempting to speculate that in the presence of minimal disease burden, pembrolizumab might still have been beneficial in our patient.
Following the third relapse and metastasectomy, our patient is currently in remission, 28 months after initiation of fourth-line regorafenib, which she tolerated well. As with our patient, previous phase 2 placebo-controlled trials demonstrate an efficacy and safety benefit of regorafenib in pretreated osteosarcoma patients. Regorafenib showed ORR between 8 and 13.6% in two phase II trials of advanced disease [ 16, 27].


This case demonstrated the importance of complete pulmonary metastasectomy in patients with relapsed osteosarcoma. Even after consecutive relapses, long-term survival can be achieved by complete metastasectomy, followed by adjuvant treatment with a TKI or CPI, without the necessity of further line chemotherapy administration. Therapy with TKI is feasible with manageable side effects. CPI treatment showed promising results in our patient; however due to previous conflicting data, further studies have to be established. Large phase III trials are necessary to confirm the status of adjuvant therapy after pulmonary metastasectomy.
Take Home Message
In relapsed osteosarcoma with lung metastasis, long-term survival can be achieved by R0 resection. In some patients adjuvant therapy with TKI is feasible with manageable side effects.

Conflict of interest

O. Steinbrecher, T. Brodowicz and W. Lamm declare that they have no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2021

memo - Magazine of European Medical Oncology 3/2021 Zur Ausgabe